{"disease":{"id":"motion-sickness","name":"Motion sickness","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":9,"pipeline_drug_count":0,"trial_count":1},"drugs":{"marketed":[{"drug_id":"dimenhydrinate","indication_name":"Motion sickness","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dimenhydrinate","generic_name":"DIMENHYDRINATE","company_name":"Alra","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"dimenhydrinate","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"buclizine","indication_name":"Motion sickness","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Buclifen","generic_name":"BUCLIZINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"buclizine","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"cyclizine","indication_name":"Motion sickness","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Marezine","generic_name":"CYCLIZINE","company_name":"GSK","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"cyclizine","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"cinnarizine","indication_name":"Motion sickness","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cinarizine","generic_name":"CINNARIZINE","company_name":"","drug_phase":"phase_2","molecular_target":"Histamine H1 receptor","drug_class":"cinnarizine","quality_score":null,"revenue":null,"mechanism":"Cinarizine works by blocking histamine receptors in the brain, which helps to reduce symptoms of motion sickness and vertigo."},{"drug_id":"parathiazine","indication_name":"Motion sickness","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pyrathiazine","generic_name":"parathiazine","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Pyrathiazine works by blocking the action of certain chemicals in the body that cause nausea and vomiting."},{"drug_id":"meclizine","indication_name":"Motion sickness","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Antivert","generic_name":"meclizine","company_name":"Generic (originally Pfizer/UCB)","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3, Serine protease hepsin, Histamine H1 receptor","drug_class":"Antihistamine/Antiemetic (vestibular suppressant)","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"meclizine","indication_name":"Prevention of Motion Sickness","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Antivert","generic_name":"meclizine","company_name":"Generic (originally Pfizer/UCB)","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3, Serine protease hepsin, Histamine H1 receptor","drug_class":"Antihistamine/Antiemetic (vestibular suppressant)","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"meclozine","indication_name":"Motion sickness","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Antivert","generic_name":"meclozine","company_name":"Citron Pharma Llc","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3","drug_class":"Antiemetic","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"meclozine","indication_name":"Prevention of Motion Sickness","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Antivert","generic_name":"meclozine","company_name":"Citron Pharma Llc","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3","drug_class":"Antiemetic","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"dimenhydrinate","indication_name":"Motion sickness","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dimenhydrinate","generic_name":"DIMENHYDRINATE","company_name":"Alra","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"dimenhydrinate","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"dimenhydrinate","indication_name":"Prevention of Motion Sickness","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dimenhydrinate","generic_name":"DIMENHYDRINATE","company_name":"Alra","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"dimenhydrinate","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"scopolamine","indication_name":"Motion sickness","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SCOPOLAMINE","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptors","drug_class":"Anticholinergic [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"scopolamin","indication_name":"Motion sickness","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"scopolamin","company_name":"University Hospital, Angers","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"scopolamin","indication_name":"Prevention of Motion Sickness","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"scopolamin","company_name":"University Hospital, Angers","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":14,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06138613","title":"Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":705,"lead_sponsor_name":"Vanda Pharmaceuticals","has_results":false},{"nct_id":"NCT05548270","title":"Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":503,"lead_sponsor_name":"Repurposed Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04327661","title":"Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":366,"lead_sponsor_name":"Vanda Pharmaceuticals","has_results":true},{"nct_id":"NCT05903924","title":"Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":316,"lead_sponsor_name":"Vanda Pharmaceuticals","has_results":true},{"nct_id":"NCT03986905","title":"The Prevention and Treatment of Nausea Associated With Motion Sickness","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Repurposed Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03755596","title":"Clinical Evaluation of the Use of Ginger Extract in the Management of Motion Sickness","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":184,"lead_sponsor_name":"Fundação Educacional Serra dos Órgãos","has_results":false},{"nct_id":"NCT04947423","title":"Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"Repurposed Therapeutics, Inc.","has_results":false},{"nct_id":"NCT02839135","title":"A Comparative Bioavailability and Adhesion Performance Study, Comparing a New Scopolamine Transdermal Delivery System Formulation to the Currently Established Reference Transdermal Delivery System in Healthy Adult Participants.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":128,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT03772340","title":"Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"Vanda Pharmaceuticals","has_results":true},{"nct_id":"NCT06056622","title":"Motion Sickness Rehabilitation for Virtual Reality","phase":"NA","overall_status":"COMPLETED","enrollment_count":121,"lead_sponsor_name":"Abant Izzet Baysal University","has_results":false},{"nct_id":"NCT04184115","title":"Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":102,"lead_sponsor_name":"Repurposed Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03988530","title":"Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":98,"lead_sponsor_name":"Repurposed Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06232785","title":"Gynecologic Endoscopic Surgery of Female Motion Sickness Patients","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"Second Hospital of Jilin University","has_results":false},{"nct_id":"NCT06128707","title":"Vestibulo-Ocular Reflex Function in Individuals With Chronic Motion Sensitivity Cross-Sectional Study","phase":"","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"Loma Linda University","has_results":false},{"nct_id":"NCT06587386","title":"The Minimum Effective Dose (ED90) of Liposomal Bupivacaine for Preserving Motor Function","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"Affiliated Hospital of Jiaxing University","has_results":false},{"nct_id":"NCT05004818","title":"Galvanic Vestibular Stimulation as a Novel Treatment for Seasickness","phase":"NA","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"Medical Corps, Israel Defense Force","has_results":false},{"nct_id":"NCT07297862","title":"Virtual Reality Sickness Questionnaire: Psychometrics in Stroke Patients","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":50,"lead_sponsor_name":"Abant Izzet Baysal University","has_results":false},{"nct_id":"NCT05622344","title":"StableEyes With Active Neurofeedback","phase":"NA","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT07318142","title":"Virtual Reality in the Rehabilitation of Visually Induced Motion Sickness","phase":"NA","overall_status":"COMPLETED","enrollment_count":46,"lead_sponsor_name":"Istanbul Aydın University","has_results":false},{"nct_id":"NCT06354309","title":"Impact of Different Types of Virtual Reality Games on Motion Sickness and Ocular in Adults: A Pilot Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"He Eye Hospital","has_results":false},{"nct_id":"NCT06892340","title":"Evaluation of a Device to Reduce Motion Sickness and Spatial Disorientation","phase":"NA","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"59th Medical Wing","has_results":false},{"nct_id":"NCT06431984","title":"Pharmacology Space Kit (PSK) - Dried Blood Spot for Caffeine Pharmacokinetics Under Microgravity Conditions","phase":"NA","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT05628220","title":"Motion Sickness Desensitization Using VR","phase":"NA","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"University Hospital, Caen","has_results":false},{"nct_id":"NCT04219982","title":"DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":23,"lead_sponsor_name":"Repurposed Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04999449","title":"Nebulizer Delivery of Intranasal Scopolamine","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Dartmouth-Hitchcock Medical Center","has_results":false},{"nct_id":"NCT05611814","title":"Preliminary Evaluation of an Osteopathic Manipulative Treatment (OMT) to Prevent Motion Sickness Symptoms","phase":"NA","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"United States Army Aeromedical Research Laboratory","has_results":false},{"nct_id":"NCT04420949","title":"Sensory Training for Visual Motion Sickness","phase":"NA","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"University of Wisconsin, Madison","has_results":true},{"nct_id":"NCT04196933","title":"Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma","phase":"NA","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Massachusetts Eye and Ear Infirmary","has_results":false}],"total":28},"guidelines":[],"source":"Drug Landscape verified database"}